← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Epivax, Inc.
Providence, RI
$18,901,078
Total funding
25
Grants
Funding over time
peak $2.3M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,601,164 · 23
FDA$1,999,984 · 1
CDC$299,930 · 1
By mechanism
R43$7,900,022 · 15
R01$5,782,647 · 2
U01$1,999,984 · 1
R21$1,633,232 · 3
R44$1,474,236 · 1
R03$67,457 · 1
Investigators at Epivax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability$1,999,984
U01 · FY2022 · FD
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,221,150
R01 · FY2017 · AI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,150,251
R01 · FY2018 · AI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,148,204
R01 · FY2019 · AI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,136,044
R01 · FY2020 · AI
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine$1,123,469
R01 · FY2021 · AI
Preclinical Studies of Tregitope Delivery and Mechanism of Action in T1D$746,662
R44 · FY2012 · DK
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of$727,574
R44 · FY2013 · DK
Novel Smallpox Vaccine Derived from VV/VAR Immunome$527,522
R43 · FY2006 · AI
Novel Smallpox Vaccine Derived from VV/VAR Immunome$499,885
R43 · FY2005 · AI
T1D Tolerance Induction with Natural Treg Epitopes$493,560
R43 · FY2008 · DK
A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE$421,437
R43 · FY2004 · AI
A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE$410,485
R43 · FY2005 · AI
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A$381,361
R43 · FY2012 · HL
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A$376,351
R43 · FY2013 · HL
A Genome-Derived, Epitope-Driven H. Pylori Vaccine$309,787
R43 · FY2006 · AI
A Genome-Derived, Epitope-Driven H. Pylori Vaccine$300,123
R43 · FY2005 · AI
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease$300,000
R43 · FY2013 · AI
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza$300,000
R43 · FY2016 · AI
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease$300,000
R43 · FY2012 · AI